“`html
Defence Therapeutics (OTCQB: DTCFF) Bolsters Leadership with Appointment of Dr. Amie Phinney to Board of Directors
Defence Therapeutics (OTCQB: DTCFF), a biotechnology firm focused on innovative drug delivery systems, announced the appointment of Dr. Amie Phinney, PhD, MBA, to its Board of Directors. Dr. Phinney, who previously served as a Strategy and Business Advisor to the company, will now expand her role to contribute to corporate governance and long-term value creation.
Defence Therapeutics has granted Dr. Phinney 100,000 stock options, immediately vested and exercisable at $0.75 per share for a three-year term, signaling confidence in her contributions to the company’s strategic direction. The appointment reinforces Defence’s leadership team as the company progresses in the development of its proprietary drug-delivery platform.
Positive
Strategic addition of experienced leader with global pharma and biotech expertise
Immediate vesting of stock options aligns new director’s interests with shareholders
Negative
Stock option grant at $0.75 represents potential dilution for existing shareholders
09/16/2025 – 03:15 AM
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF), a company specializing in drug delivery technologies, has appointed Dr. Amie Phinney, PhD, MBA to its Board of Directors effective immediately.
Dr. Phinney recently joined Defence as a Strategy and Business Advisor, with responsibilities to refine the company’s strategic direction. Expanding her role to the Board of Directors, she will assist driving governance and long-term value creation as Defence advances its drug-delivery platform.
“Amie has already made a notable impact on shaping our strategic priorities,” stated Sébastien Plouffe, Founder and CEO of Defence Therapeutics. “Her diverse experience spanning global pharma, biotech ventures, and commercialization will be invaluable as we continue to build the company.”
“I am honoured to join the Board at this pivotal stage,” said Dr. Phinney. “Defence’s science holds potential and I look forward to supporting the company’s growth and long-term prospects.”
With Dr. Phinney’s appointment, Defence aims to enhance its leadership team and Board’s capabilities, particularly as it aims to translate its developed drug-delivery science, potentially impacting treatment landscapes while creating value for patients and shareholders.
The Company has granted 100,000 incentive stock options to Dr. Phinney (the “Options”), under the terms of Defence’s Omnibus Incentive Plan. The Options are vested and exercisable at a price of $0.75 per share for a period of three years.
**About Defence:**
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing next-generation ADC products utilizing its proprietary platform. Defence Therapeutics’ platform is the ACCUM® technology, which enables targeted delivery of ADCs.
**Investment Thesis and Market Context**
Defence Therapeutics’ focus on innovative drug delivery platforms, particularly its ACCUM® technology, positions it within a rapidly evolving biotechnology landscape. Targeted drug delivery systems are gaining traction due to their potential to enhance efficacy while minimizing systemic toxicity, a critical consideration for many oncology therapeutics. The appointment of Dr. Phinney, with her experience in commercialization and strategic development, suggests a commitment to not only scientific advancement but also realizing market potential. Investors will likely watch for progress on clinical trials, partnerships, and regulatory milestones as key indicators of the company’s ability to translate its technological advantage into tangible value. However, like other biotechnology companies, Defence Therapeutics faces the risks associated with clinical development, regulatory approvals, and market adoption, underlining the importance of portfolio diversification and risk management strategies for investors.
Cautionary Statement Regarding “Forward-Looking” Information
This release includes certain statements may be “forward-looking statements”. All statements in other than historical events, that address events developments expected, are forward-looking statements. Forward-looking statements are not historical facts and are generally use statements such as “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and other similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company anticipates based on expectations, such statement is not a guarantee of results. Investor are cution that the actual results or developments may differ from projected in the forward-looking statements based on the beliefs. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements.
FAQ
Who is Dr. Amie Phinney and what is her new role at Defence Therapeutics (DTCFF)?
Dr. Amie Phinney, PhD, MBA, has been appointed to Defence Therapeutics’ Board of Directors. She will help drive governance and long-term value creation.
What stock options were granted to Dr. Phinney by Defence Therapeutics?
Defence Therapeutics granted Dr. Phinney 100,000 stock options vesting at $0.75 per share for a three-year period.
How will Dr. Phinney’s appointment benefit Defence Therapeutics (DTCFF)?
Dr. Phinney brings experience in global pharma, biotech ventures, and commercialization, which will help Defence advance its drug-delivery platform.
What is Defence Therapeutics’ main business focus?
Defence Therapeutics is a biotechnology company specializing in drug delivery technologies that could develop treatment solutions.
